Skip to main content
Open Access Publications from the University of California

Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

  • Author(s): Wolstein, Orit
  • Boyd, Maureen
  • Millington, Michelle
  • Impey, Helen
  • Boyer, Joshua
  • Howe, Annett
  • Delebecque, Frederic
  • Cornetta, Kenneth
  • Rothe, Michael
  • Baum, Christopher
  • Nicolson, Tamara
  • Koldej, Rachel
  • Zhang, Jane
  • Keech, Naomi
  • Camba Colón, Joanna
  • Breton, Louis
  • Bartlett, Jeffrey
  • An, Dong Sung
  • Chen, Irvin Sy
  • Burke, Bryan
  • Symonds, Geoff P
  • et al.

Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are resistant to the virus. We have engineered a novel self-inactivating lentiviral vector, LVsh5/C46, using two viral-entry inhibitors to block early steps of HIV-1 cycle. The LVsh5/C46 vector encodes a short hairpin RNA (shRNA) for downregulation of CCR5, in combination with the HIV-1 fusion inhibitor, C46. We demonstrate here the effective delivery of LVsh5/C46 to human T cell lines, peripheral blood mononuclear cells, primary CD4(+) T lymphocytes, and CD34(+) hematopoietic stem/progenitor cells (HSPC). CCR5-targeted shRNA (sh5) and C46 peptide were stably expressed in the target cells and were able to effectively protect gene-modified cells against infection with CCR5- and CXCR4-tropic strains of HIV-1. LVsh5/C46 treatment was nontoxic as assessed by cell growth and viability, was noninflammatory, and had no adverse effect on HSPC differentiation. LVsh5/C46 could be produced at a scale sufficient for clinical development and resulted in active viral particles with very low mutagenic potential and the absence of replication-competent lentivirus. Based on these in vitro results, plus additional in vivo safety and efficacy data, LVsh5/C46 is now being tested in a phase 1/2 clinical trial for the treatment of HIV-1 disease.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View